Selected research
Market Outlook & Growth Opportunities
Global Neuraminidase Inhibitors Drug Market Outlook and Growth Opportunities 2026
Market perspective
The global Neuraminidase Inhibitors Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Neuraminidase Inhibitors Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Neuraminidase Inhibitors Drug market include Teva, Roche, Pfizer, GSK, AstraZeneca, Sun Pharmaceutical, Gilead Sciences, Daiichi Sankyo and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Neuraminidase Inhibitors Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neuraminidase Inhibitors Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neuraminidase Inhibitors Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuraminidase Inhibitors Drug market.
Neuraminidase Inhibitors Drug Segment by Company
Teva
Roche
Pfizer
GSK
AstraZeneca
Sun Pharmaceutical
Gilead Sciences
Daiichi Sankyo
Bristol-Myers Squibb
Neuraminidase Inhibitors Drug Segment by Type
Oseltamivir
Laninamivir
Peramivir
Zanamivir
Neuraminidase Inhibitors Drug Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
Neuraminidase Inhibitors Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Neuraminidase Inhibitors Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Neuraminidase Inhibitors Drug key companies, revenue, market share, and recent developments.
3. To split the Neuraminidase Inhibitors Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Neuraminidase Inhibitors Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neuraminidase Inhibitors Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Neuraminidase Inhibitors Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitors Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuraminidase Inhibitors Drug industry.
Chapter 3: Detailed analysis of Neuraminidase Inhibitors Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Neuraminidase Inhibitors Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Neuraminidase Inhibitors Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Neuraminidase Inhibitors Drug Industry Trends
Table 2. Neuraminidase Inhibitors Drug Industry Drivers
Table 3. Neuraminidase Inhibitors Drug Industry Opportunities and Challenges
Table 4. Neuraminidase Inhibitors Drug Industry Restraints
Table 5. Global Neuraminidase Inhibitors Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Neuraminidase Inhibitors Drug Revenue Share by Company (2021-2026)
Table 7. Global Neuraminidase Inhibitors Drug Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Neuraminidase Inhibitors Drug Key Company Manufacturing Base & Headquarters
Table 9. Global Neuraminidase Inhibitors Drug Company, Product Type & Application
Table 10. Global Neuraminidase Inhibitors Drug Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Neuraminidase Inhibitors Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Oseltamivir
Table 15. Significant Companies of Laninamivir
Table 16. Significant Companies of Peramivir
Table 17. Significant Companies of Zanamivir
Table 18. Global Neuraminidase Inhibitors Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 19. Global Neuraminidase Inhibitors Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 20. Global Neuraminidase Inhibitors Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 21. Global Neuraminidase Inhibitors Drug Sales Value Share by Type (2021-2026)
Table 22. Global Neuraminidase Inhibitors Drug Sales Value Share by Type (2027-2032)
Table 23. Significant Companies of Hospital Pharmacy
Table 24. Significant Companies of Online Pharmacy
Table 25. Significant Companies of Retail Pharmacy
Table 26. Significant Companies of Others
Table 27. Global Neuraminidase Inhibitors Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 28. Global Neuraminidase Inhibitors Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 29. Global Neuraminidase Inhibitors Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 30. Global Neuraminidase Inhibitors Drug Sales Value Share by Application (2021-2026)
Table 31. Global Neuraminidase Inhibitors Drug Sales Value Share by Application (2027-2032)
Table 32. Global Neuraminidase Inhibitors Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 33. Global Neuraminidase Inhibitors Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 34. Global Neuraminidase Inhibitors Drug Sales Value Share by Region (2021-2026)
Table 35. Global Neuraminidase Inhibitors Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 36. Global Neuraminidase Inhibitors Drug Sales Value Share by Region (2027-2032)
Table 37. Global Neuraminidase Inhibitors Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Neuraminidase Inhibitors Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 39. Global Neuraminidase Inhibitors Drug Sales Value Market Share by Country (2021-2026)
Table 40. Global Neuraminidase Inhibitors Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 41. Global Neuraminidase Inhibitors Drug Sales Value Market Share by Country (2027-2032)
Table 42. Teva Company Information
Table 43. Teva Business Overview
Table 44. Teva Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 45. Teva Neuraminidase Inhibitors Drug Product Portfolio
Table 46. Teva Recent Development
Table 47. Roche Company Information
Table 48. Roche Business Overview
Table 49. Roche Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. Roche Neuraminidase Inhibitors Drug Product Portfolio
Table 51. Roche Recent Development
Table 52. Pfizer Company Information
Table 53. Pfizer Business Overview
Table 54. Pfizer Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 55. Pfizer Neuraminidase Inhibitors Drug Product Portfolio
Table 56. Pfizer Recent Development
Table 57. GSK Company Information
Table 58. GSK Business Overview
Table 59. GSK Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 60. GSK Neuraminidase Inhibitors Drug Product Portfolio
Table 61. GSK Recent Development
Table 62. AstraZeneca Company Information
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio
Table 66. AstraZeneca Recent Development
Table 67. Sun Pharmaceutical Company Information
Table 68. Sun Pharmaceutical Business Overview
Table 69. Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 70. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio
Table 71. Sun Pharmaceutical Recent Development
Table 72. Gilead Sciences Company Information
Table 73. Gilead Sciences Business Overview
Table 74. Gilead Sciences Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 75. Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio
Table 76. Gilead Sciences Recent Development
Table 77. Daiichi Sankyo Company Information
Table 78. Daiichi Sankyo Business Overview
Table 79. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio
Table 81. Daiichi Sankyo Recent Development
Table 82. Bristol-Myers Squibb Company Information
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 85. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio
Table 86. Bristol-Myers Squibb Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Authors List of This Report
Table 89. Secondary Sources
Table 90. Primary Sources
List of Figures
Figure 1. Neuraminidase Inhibitors Drug Product Image
Figure 2. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Neuraminidase Inhibitors Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Oseltamivir Image
Figure 8. Laninamivir Image
Figure 9. Peramivir Image
Figure 10. Zanamivir Image
Figure 11. Global Neuraminidase Inhibitors Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 12. Global Neuraminidase Inhibitors Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 13. Global Neuraminidase Inhibitors Drug Sales Value Share by Type (2021-2032)
Figure 14. Hospital Pharmacy Image
Figure 15. Online Pharmacy Image
Figure 16. Retail Pharmacy Image
Figure 17. Others Image
Figure 18. Global Neuraminidase Inhibitors Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Neuraminidase Inhibitors Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Neuraminidase Inhibitors Drug Sales Value Share by Application (2021-2032)
Figure 21. Global Neuraminidase Inhibitors Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 22. Global Neuraminidase Inhibitors Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 23. North America Neuraminidase Inhibitors Drug Sales Value (2021-2032) & (US$ Million)
Figure 24. North America Neuraminidase Inhibitors Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Europe Neuraminidase Inhibitors Drug Sales Value (2021-2032) & (US$ Million)
Figure 26. Europe Neuraminidase Inhibitors Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Asia-Pacific Neuraminidase Inhibitors Drug Sales Value (2021-2032) & (US$ Million)
Figure 28. Asia-Pacific Neuraminidase Inhibitors Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 29. South America Neuraminidase Inhibitors Drug Sales Value (2021-2032) & (US$ Million)
Figure 30. South America Neuraminidase Inhibitors Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Middle East & Africa Neuraminidase Inhibitors Drug Sales Value (2021-2032) & (US$ Million)
Figure 32. Middle East & Africa Neuraminidase Inhibitors Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 33. USA Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. USA Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. USA Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Canada Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Canada Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Canada Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Mexico Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Mexico Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Mexico Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Germany Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Germany Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Germany Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. France Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. France Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. France Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. U.K. Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. U.K. Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. U.K. Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Italy Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Italy Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Italy Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Spain Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Spain Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Spain Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Russia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Russia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Russia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Netherlands Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Netherlands Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Netherlands Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Nordic Countries Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Nordic Countries Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. China Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. China Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. China Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. Japan Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. Japan Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. Japan Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. South Korea Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. South Korea Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. South Korea Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. India Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. India Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. India Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Australia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Australia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Australia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Southeast Asia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Southeast Asia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Brazil Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Brazil Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Brazil Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Argentina Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Argentina Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Argentina Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Chile Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Chile Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Chile Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Colombia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Colombia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Colombia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Peru Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Peru Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Peru Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Saudi Arabia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Saudi Arabia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Israel Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Israel Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Israel Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. UAE Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. UAE Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. UAE Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Turkey Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Turkey Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Turkey Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Iran Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Iran Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Iran Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Egypt Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Egypt Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Egypt Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Years Considered
Figure 118. Research Process
Figure 119. Key Executives Interviewed
Scope & coverage.
Types
- Oseltamivir
- Laninamivir
- Peramivir
- Zanamivir
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Companies covered
- Teva
- Roche
- Pfizer
- GSK
- AstraZeneca
- Sun Pharmaceutical
- Gilead Sciences
- Daiichi Sankyo
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuraminidase Inhibitors Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neuraminidase Inhibitors Drug Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Neuraminidase Inhibitors Drug Market Dynamics
- 2.1 Neuraminidase Inhibitors Drug Industry Trends
- 2.2 Neuraminidase Inhibitors Drug Industry Drivers
- 2.3 Neuraminidase Inhibitors Drug Industry Opportunities and Challenges
- 2.4 Neuraminidase Inhibitors Drug Industry Restraints
3 Neuraminidase Inhibitors Drug Market by Company
- 3.1 Global Neuraminidase Inhibitors Drug Company Revenue Ranking in 2025
- 3.2 Global Neuraminidase Inhibitors Drug Revenue by Company (2021-2026)
- 3.3 Global Neuraminidase Inhibitors Drug Company Ranking (2024-2026)
- 3.4 Global Neuraminidase Inhibitors Drug Company Manufacturing Base and Headquarters
- 3.5 Global Neuraminidase Inhibitors Drug Company Product Type and Application
- 3.6 Global Neuraminidase Inhibitors Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Neuraminidase Inhibitors Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Neuraminidase Inhibitors Drug Market by Type
- 4.1 Neuraminidase Inhibitors Drug Type Introduction
- 4.1.1 Oseltamivir
- 4.1.2 Laninamivir
- 4.1.3 Peramivir
- 4.1.4 Zanamivir
- 4.2 Global Neuraminidase Inhibitors Drug Sales Value by Type
- 4.2.1 Global Neuraminidase Inhibitors Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neuraminidase Inhibitors Drug Sales Value by Type (2021-2032)
- 4.2.3 Global Neuraminidase Inhibitors Drug Sales Value Share by Type (2021-2032)
5 Neuraminidase Inhibitors Drug Market by Application
- 5.1 Neuraminidase Inhibitors Drug Application Introduction
- 5.1.1 Hospital Pharmacy
- 5.1.2 Online Pharmacy
- 5.1.3 Retail Pharmacy
- 5.1.4 Others
- 5.2 Global Neuraminidase Inhibitors Drug Sales Value by Application
- 5.2.1 Global Neuraminidase Inhibitors Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neuraminidase Inhibitors Drug Sales Value by Application (2021-2032)
- 5.2.3 Global Neuraminidase Inhibitors Drug Sales Value Share by Application (2021-2032)
6 Neuraminidase Inhibitors Drug Regional Value Analysis
- 6.1 Global Neuraminidase Inhibitors Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neuraminidase Inhibitors Drug Sales Value by Region (2021-2032)
- 6.2.1 Global Neuraminidase Inhibitors Drug Sales Value by Region: 2021-2026
- 6.2.2 Global Neuraminidase Inhibitors Drug Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neuraminidase Inhibitors Drug Sales Value (2021-2032)
- 6.3.2 North America Neuraminidase Inhibitors Drug Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Neuraminidase Inhibitors Drug Sales Value (2021-2032)
- 6.4.2 Europe Neuraminidase Inhibitors Drug Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Neuraminidase Inhibitors Drug Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Neuraminidase Inhibitors Drug Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Neuraminidase Inhibitors Drug Sales Value (2021-2032)
- 6.6.2 South America Neuraminidase Inhibitors Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Neuraminidase Inhibitors Drug Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Neuraminidase Inhibitors Drug Sales Value Share by Country, 2025 VS 2032
7 Neuraminidase Inhibitors Drug Country-level Value Analysis
- 7.1 Global Neuraminidase Inhibitors Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Neuraminidase Inhibitors Drug Sales Value by Country (2021-2032)
- 7.2.1 Global Neuraminidase Inhibitors Drug Sales Value by Country (2021-2026)
- 7.2.2 Global Neuraminidase Inhibitors Drug Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.7.2 France Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 China Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 India Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Neuraminidase Inhibitors Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Neuraminidase Inhibitors Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Neuraminidase Inhibitors Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Teva
- 8.1.1 Teva Company Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Neuraminidase Inhibitors Drug Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 Roche
- 8.2.1 Roche Company Information
- 8.2.2 Roche Business Overview
- 8.2.3 Roche Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.2.4 Roche Neuraminidase Inhibitors Drug Product Portfolio
- 8.2.5 Roche Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Neuraminidase Inhibitors Drug Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 GSK
- 8.4.1 GSK Company Information
- 8.4.2 GSK Business Overview
- 8.4.3 GSK Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.4.4 GSK Neuraminidase Inhibitors Drug Product Portfolio
- 8.4.5 GSK Recent Developments
- 8.5 AstraZeneca
- 8.5.1 AstraZeneca Company Information
- 8.5.2 AstraZeneca Business Overview
- 8.5.3 AstraZeneca Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.5.4 AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio
- 8.5.5 AstraZeneca Recent Developments
- 8.6 Sun Pharmaceutical
- 8.6.1 Sun Pharmaceutical Company Information
- 8.6.2 Sun Pharmaceutical Business Overview
- 8.6.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.6.4 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio
- 8.6.5 Sun Pharmaceutical Recent Developments
- 8.7 Gilead Sciences
- 8.7.1 Gilead Sciences Company Information
- 8.7.2 Gilead Sciences Business Overview
- 8.7.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.7.4 Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio
- 8.7.5 Gilead Sciences Recent Developments
- 8.8 Daiichi Sankyo
- 8.8.1 Daiichi Sankyo Company Information
- 8.8.2 Daiichi Sankyo Business Overview
- 8.8.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.8.4 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio
- 8.8.5 Daiichi Sankyo Recent Developments
- 8.9 Bristol-Myers Squibb
- 8.9.1 Bristol-Myers Squibb Company Information
- 8.9.2 Bristol-Myers Squibb Business Overview
- 8.9.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
- 8.9.4 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio
- 8.9.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst